Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. 

We are a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in anti FcRn technology, we are developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

Immunovant’s investigational product, imeroprubart (IMVT-1402), is a novel, fully human, monoclonal antibody that targets FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe this candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection with dosing that may be tailored based on disease stage and severity.